Literature DB >> 12645228

Problems for biomedical research at the academia-industrial interface.

David Weatherall1.   

Abstract

Throughout much of the world, universities have driven towards industrial partnerships. This collaboration, which, in the biochemical field at least, has to continue if potential benefits for patients are to be realised, has brought with it a number of problems. These include the neglect of long-term research in favour of short-term projects, the curtailing of free dissemination of research information within university departments and the biasing of results of clinical trials by the financial interests of the investigators. It is very important that governments, universities, and industry itself address these problems. Universities should monitor the amount of basic, curiosity-driven research that is being carried on, compared with that which is more short-term goal orientated. PhD students and post-doctoral fellows should be exposed to the principles of bioethics early on in their careers. Further work is necessary on the terms of research contracts to protect, on the one hand, the rights of individual scientists and, on the other, industry from rogue scientists. Where problems arise, procedures should be in place for independent reviews to be conducted by bodies such as the Medical Research Council in the UK or the National Institutes of Health in the USA. The conflict-of-interest rules recently introduced for publication in medical journals should be extended to all branches of science.

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh:

Year:  2003        PMID: 12645228     DOI: 10.1007/s11948-003-0018-9

Source DB:  PubMed          Journal:  Sci Eng Ethics        ISSN: 1353-3452            Impact factor:   3.525


  10 in total

1.  Med school to relax rules on business links?

Authors:  S Nadis
Journal:  Nature       Date:  2000-02-24       Impact factor: 49.962

2.  Conflict of interest. NEJM admits breaking its own tough rules.

Authors:  C Holden
Journal:  Science       Date:  2000-03-03       Impact factor: 47.728

3.  Gene therapy institute denies that errors led to trial death.

Authors:  P Smaglik
Journal:  Nature       Date:  2000-02-24       Impact factor: 49.962

4.  Is academic medicine for sale?

Authors:  M Angell
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

5.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

6.  Is the university-industrial complex out of control?

Authors: 
Journal:  Nature       Date:  2001-01-11       Impact factor: 49.962

7.  Pharmaceutical industry-sponsored meetings: good value or just a free meal?

Authors:  S L Carney; K R Nair; M A Sales; J Walsh
Journal:  Intern Med J       Date:  2001-11       Impact factor: 2.048

8.  Sponsorship, authorship, and accountability.

Authors:  F Davidoff; C D DeAngelis; J M Drazen; J Hoey; L Højgaard; R Horton; S Kotzin; M G Nicholls; M Nylenna; A J Overbeke; H C Sox; M B Van Der Weyden; M S Wilkes
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

9.  Conflict of interest in the debate over calcium-channel antagonists.

Authors:  H T Stelfox; G Chua; K O'Rourke; A S Detsky
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245

10.  Patients' health or company profits? The commercialisation of academic research.

Authors:  Nancy F Olivieri
Journal:  Sci Eng Ethics       Date:  2003-01       Impact factor: 3.525

  10 in total
  6 in total

1.  Ethical issues at the university-industry interface: a way forward?

Authors:  G R Evans; D E Packham
Journal:  Sci Eng Ethics       Date:  2003-01       Impact factor: 3.525

2.  G.A.T.S. and universities: implications for research.

Authors:  David E Packham
Journal:  Sci Eng Ethics       Date:  2003-01       Impact factor: 3.525

3.  Patients' health or company profits? The commercialisation of academic research.

Authors:  Nancy F Olivieri
Journal:  Sci Eng Ethics       Date:  2003-01       Impact factor: 3.525

4.  Financial considerations in the conduct of multi-centre randomised controlled trials: evidence from a qualitative study.

Authors:  Claire Snowdon; Diana R Elbourne; Jo Garcia; Marion K Campbell; Vikki A Entwistle; David Francis; Adrian M Grant; Rosemary C Knight; Alison M McDonald; Ian Roberts
Journal:  Trials       Date:  2006-12-21       Impact factor: 2.279

5.  Basic Blue Skies Research in the UK: Are we losing out?

Authors:  Belinda Linden
Journal:  J Biomed Discov Collab       Date:  2008-02-29

Review 6.  Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer.

Authors:  Stefanie Broes; Robbe Saesen; Denis Lacombe; Isabelle Huys
Journal:  Clin Transl Sci       Date:  2020-08-29       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.